(Press-News.org) CINCINNATI—Researchers at the University of Cincinnati (UC) and Massachusetts General Hospital have found that warfarin, a known anticoagulation (blood-thinning) drug, may not be as beneficial to some patients with atrial fibrillation as previously thought.
These findings were published online this week ahead of print in the journal Circulation: Cardiovascular Quality and Outcomes.
Warfarin is commonly prescribed to prevent blood clotting, particularly for patients with atrial fibrillation—a type of abnormal heart rhythm.
Mark Eckman, MD, professor of medicine at UC and lead investigator of the study, says that this finding could change the way patients with the heart condition manage stroke risk.
"When considering patient-specific decision making for patients with atrial fibrillation, patients at lower risk of stroke and at high risk of bleeding should not receive oral anticoagulant therapy; patients at higher risk of stroke and at low risk of bleeding should receive anticoagulant therapy," he says. "The more difficult decisions lie in the middle where the risks of stroke and bleeding are more closely balanced. Here lies the so-called 'tipping point.'
"Our goal was to revisit the tipping point in light of more contemporary data suggesting a declining stroke risk for any of the typically defined risk factors. We also wished to explore how the future availability of a new, safer anticoagulant, such as the direct thrombin inhibitor dabigatran, in the United States would impact anticoagulant therapy."
Eckman and researchers used a Markov state transition decision model—a mathematical framework for modeling decision-making in situations where outcomes are partly due to chance and partly under the control of a decision maker—to analyze the CHADS2 score above which anticoagulation is preferred.
The CHADS2 model is used to estimate stroke risk in patients with atrial fibrillation.
"CHADS2 takes into account the patient's age as well as other medical conditions, including congestive heart failure, hypertension, diabetes and prior stroke and is used by many guidelines to help make treatment recommendations for anticoagulant or blood-thinning therapy," Eckman says, adding that researchers also used outcomes from the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study to define a more contemporary risk of stroke among patients with atrial fibrillation.
The ATRIA study has followed outcomes in a large group of more than 13,500 patients with atrial fibrillation and has found that the risk of stroke has declined over the past two decades.
Researchers explored outcomes of four strategies: anticoagulate with warfarin; anticoagulate with a new, "safer" agent, using dabigatran (another anticoagulant) as the prototype; treat with aspirin; and no antithrombotic therapy.
"We used a standard computer program to build the model, analyze results and perform sensitivity analyses," Eckman says. "Our base case involved a hypothetical 69-year-old man with non-valvular atrial fibrillation who had no contraindications to warfarin therapy."
Researchers found that warfarin is preferred above a stroke rate of 1.7 percent per year, corresponding to a CHADS2 score of 0 using the historically higher rates of stroke of the older CHADS2 derivation cohort.
Eckman continues, "Using more contemporary and lower estimates of stroke risk raises the threshold for use of warfarin to a CHADS2 score of greater than or equal to 2 (moderate to high risk). However, anticoagulation with a new, 'safer' agent leads to a lowering of the threshold for anticoagulation to a stroke rate of 0.9 percent per year.
"Our analysis suggests that the 'tipping point,' the threshold of ischemic stroke risk below which anticoagulant therapy should be withheld and above which anticoagulant therapy should be prescribed, has changed," he says. "The risk of ischemic stroke in non-valvular atrial fibrillation appears to have declined, perhaps as a result of more aggressive control of blood pressure and lipid levels. Our analysis, using a more contemporary group of patients with atrial fibrillation from the ATRIA study, suggests that the threshold has shifted such that the balance of risk and benefit of anticoagulation tips in favor of warfarin at a higher CHADS2 score than in the past."
However, he says that as safer anticoagulants become available, the tipping point will shift again.
"With the advent of new anticoagulants and antithrombotic therapies, along with non-pharmacological interventions for atrial fibrillation, and the improbability of clinical trials performing head-to-head comparisons of these treatments, a decision-analytical framework may be one of the few ways to compare new treatments as they become available," he says."These data have implications for future guidelines as well as real-world bedside decision-making."
INFORMATION:
The investigators were supported by the National Center for Research Resources, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Heart, Lung, and Blood Institute, and the National Library of Medicine.
Eckman has consulted for Savient Pharmaceuticals and has received research support from Gilead Sciences, Inc.
END
Alzheimer and heart attacks have been found to share common genetic basis. The research leads the way to the first genetic test on developing the risk of the diseases even at a young age. According to Federico Licastro, an immunologist at the University of Bologna who coordinated the study published in the scientific journal, Journal of Alzheimer's Disease, a test is now ready. "They are already selling it in America", he says, citing the case of a private firm in New Mexico (USA) that collaborated on the study. "But the tests could easily be also conducted wherever, using ...
(Santa Barbara, Calif.) –– Remarkable progress in understanding how stem cell biology works has been reported by a team of leading scientists, directed by experts at UC Santa Barbara. Their research has been published in the journal Cell Stem Cell.
Stem cell biology is making waves around the world with great hope for the eventual repair of parts of the body. While many scientists see these breakthroughs as viable, there are hurdles that must be overcome, including the worrisome potential for introducing cancer when making a repair to an organ.
Significant interdisciplinary ...
Scientists at the Virginia Bioinformatics Institute at Virginia Tech have discovered some of the key molecular events in the immune system that contribute to inflammatory bowel disease. The results, which help researchers move one step further in their efforts to develop new drugs to treat inflammatory and immune-mediated diseases, are reported in the November 2010 edition (http://www.ncbi.nlm.nih.gov/pubmed/21068720) of the journal Mucosal Immunology from the Nature Publishing Group.
Inflammatory bowel disease starts when the gut initiates an abnormal immune response ...
Researchers at the Virginia Bioinformatics Institute at Virginia Tech have discovered how abscisic acid, a natural plant hormone with known beneficial properties for the treatment of disease, helps fight inflammation. The results (http://www.ncbi.nlm.nih.gov/pubmed/210882970), which are published in the November 2010 Journal of Biological Chemistry, reveal important new drug targets for the development of treatments for inflammatory and immune-mediated diseases.
The scientists had reported some of the key molecular events in the immune system of mice that contribute to ...
ALBUQUERQUE, N.M. — A benchtop version of the world's smallest battery — its anode a single nanowire one seven-thousandth the thickness of a human hair —has been created by a team led by Sandia National Laboratories researcher Jianyu Huang.
To better study the anode's characteristics, the tiny rechargeable, lithium-based battery was formed inside a transmission electron microscope (TEM) at the Center for Integrated Nanotechnologies (CINT), a Department of Energy research facility jointly operated by Sandia and Los Alamos national laboratories.
Says Huang of the work, ...
DURHAM, N.C. – Using lasers to contain some ultra-chilled atoms, a team of scientists has measured the viscosity or stickiness of a gas often considered to be the sixth state of matter. The measurements verify that this gas can be used as a "scale model" of exotic matter, such as super-high temperature superconductors, the nuclear matter of neutron stars, and even the state of matter created microseconds after the Big Bang.
The results may also allow experimental tests of string theory in the future.
Duke physicist John Thomas made the viscosity measurements using an ...
Despite a 30-year warming trend, the last three years in the Bering Sea have been the coldest on record. A University of Alaska Fairbanks scientist says that the cold temperatures have helped produce larger zooplankton in the Bering Sea, which may affect the way Walleye pollock feed.
Alexei Pinchuk, research professional at the UAF Seward Marine Center, has spent the last three years gathering zooplankton samples in the Bering Sea. He and his colleagues have been looking at how changes in temperature in the Bering Sea affect resident zooplankton and, in turn, how those ...
New research suggests that private industry and academic science pursue different goals with different consequences, but that the two can still be complementary.
Over the past three decades, private funding and collaboration in university-based research has risen steadily. That has led to concerns about the independence and integrity of public science. However, University of Chicago sociologist James Evans finds that industry can advance academic science by shaking up its conservative nature and encouraging novel discovery.
Evans's research, released today in the American ...
OAK RIDGE, Tenn., Dec. 9, 2010 -- A quicker and cheaper technique to scan molecular databases developed at the Department of Energy's Oak Ridge National Laboratory could put scientists on the fast track to developing new drug treatments.
A team led by Jerome Baudry of the University of Tennessee-ORNL Center for Molecular Biophysics adapted a widely used existing software to allow supercomputers such as ORNL's Jaguar to sift through immense molecular databases and pinpoint chemical compounds as potential drug candidates.
The research was published in the Journal of ...
Used in the proper amounts, it can make teeth stronger and aid in the treatment of osteoporosis. When excessive amounts are consumed, however, it can be a killer — a carcinogen that causes bone, lung and bladder cancers. The "it" is fluoride, a common additive in most American communities' drinking water and an ingredient in the vast majority of commercially produced adult toothpastes.
Determining the level of fluoride, be it in water, consumer products or the human body, is an important and attractive challenge for scientists. To address that, a Florida State University ...
